1522 related articles for article (PubMed ID: 9443413)
41. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
Wu WG; Soria JC; Wang L; Kemp BL; Mao L
Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
[TBL] [Abstract][Full Text] [Related]
42. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
43. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
[TBL] [Abstract][Full Text] [Related]
44. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
45. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.
Marchetti A; Buttitta F; Merlo G; Diella F; Pellegrini S; Pepe S; Macchiarini P; Chella A; Angeletti CA; Callahan R
Cancer Res; 1993 Jun; 53(12):2846-51. PubMed ID: 8389245
[TBL] [Abstract][Full Text] [Related]
46. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
[TBL] [Abstract][Full Text] [Related]
47. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
48. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
[TBL] [Abstract][Full Text] [Related]
49. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.
Takahashi T; Takahashi T; Suzuki H; Hida T; Sekido Y; Ariyoshi Y; Ueda R
Oncogene; 1991 Oct; 6(10):1775-8. PubMed ID: 1656362
[TBL] [Abstract][Full Text] [Related]
50. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer.
Lee LN; Shew JY; Sheu JC; Lee YC; Lee WC; Fang MT; Chang HF; Yu CJ; Yang PC; Luh KT
Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1667-71. PubMed ID: 7952630
[TBL] [Abstract][Full Text] [Related]
51. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
52. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
53. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
54. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
55. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
[TBL] [Abstract][Full Text] [Related]
56. Gender differences in p53 mutational status in small cell lung cancer.
Tseng JE; Rodriguez M; Ro J; Liu D; Hong WK; Mao L
Cancer Res; 1999 Nov; 59(22):5666-70. PubMed ID: 10582680
[TBL] [Abstract][Full Text] [Related]
57. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
58. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
59. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Bodner SM; Minna JD; Jensen SM; D'Amico D; Carbone D; Mitsudomi T; Fedorko J; Buchhagen DL; Nau MM; Gazdar AF
Oncogene; 1992 Apr; 7(4):743-9. PubMed ID: 1565469
[TBL] [Abstract][Full Text] [Related]
60. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Lerman MI; Minna JD
Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
